News

Sanofi SAN1.00%increase; green up pointing triangle agreed to buy Blueprint Medicines BPMC-0.15%decrease; red down pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...
Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC ...
As per Sanofi’s statement, the deal involves a cash payment of USD129 per share, representing a roughly 27 percent premium over Blueprint’s most recent closing stock price of USD101.35.
LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
Blueprint’s CEO, Kate Haviland, expressed pride in the company’s innovations and collaborations that have improved patient outcomes. She anticipates that the merger with Sanofi will accelerate their ...
Sanofi acquires Blueprint Medicines for $9.1 billion, gaining Ayvakit, a rare disease treatment approved in the US and EU for multiple conditions.
The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.
Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.
Sanofi acquires Blueprint Medicines for $9.1 billion, ... The French pharmaceutical giant struck a deal to buy the Cambridge biotech for about $9.1 billion, or $129 per share.